(Q37464749)

20 August 2017

1 reference

title

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia (English)

1 reference

20 August 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

1 reference

1 reference

J E Cortes

1

1 reference

20 August 2017

M J Egorin

2

1 reference

20 August 2017

F Guilhot

3

1 reference

20 August 2017

M Molimard

4

1 reference

20 August 2017

F-X Mahon

5

1 reference

20 August 2017

30 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

23

1 reference

20 August 2017

9

1 reference

20 August 2017

1537-1544

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.88

20 August 2017

0 references

cites work

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Multifaceted approach to the treatment of bcr-abl-positive leukemias.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Chronic myeloid leukaemia as a model of disease evolution in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Gene expression changes associated with progression and response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Imatinib therapy in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Clinical pharmacokinetics of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Adherence to therapy with oral antineoplastic agents

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Compliance with oral drug therapy in patients with hematologic malignancy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Effect of St John's wort on imatinib mesylate pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Therapeutic drug monitoring in CML patients on imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Interaction of imatinib mesilate with human P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

hOCT 1 and resistance to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.88

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.88

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference